Focus: Reviva Pharmaceuticals is a public biotech focused on small-molecule therapeutics for neurology, primarily schizophrenia. The company is currently transitioning from Nasdaq to OTCQB trading following delisting pressure.
Profile data last refreshed 19h ago · AI intelligence enriched 3w ago
No open roles listed right now. Follow Reviva Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Reviva Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Reviva Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th - GlobeNewswire
Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th GlobeNewswire
Brilaroxazine patent filing may extend to 2046 as Reviva moves from Nasdaq to OTCQB - Stock Titan
Brilaroxazine patent filing may extend to 2046 as Reviva moves from Nasdaq to OTCQB Stock Titan
RVPH|Reviva Pharmaceuticals Holdings Inc|Price:0.352| - TradingKey
RVPH|Reviva Pharmaceuticals Holdings Inc|Price:0.352| TradingKey
Reviva Pharmaceuticals (NASDAQ: RVPH) faces Nasdaq delisting, moves to OTCQB - Stock Titan
Reviva Pharmaceuticals (NASDAQ: RVPH) faces Nasdaq delisting, moves to OTCQB Stock Titan
Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewswire
Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights GlobeNewswire
Reviva (NASDAQ: RVPH) trims Q1 2026 loss and shifts listing to OTCQB - Stock Titan
Reviva (NASDAQ: RVPH) trims Q1 2026 loss and shifts listing to OTCQB Stock Titan
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo